Oct. 26 at 1:57 AM
$RVTY "Heads up alert! Only two days until Upcoming earnings on Monday, 10/27/2025 for
$RVTY
Neutral (5.5)
---
Revvity, Inc.
(NYSE: RVTY) is navigating a complex landscape characterized by both opportunities and challenges.
The company recently declared a quarterly dividend of
$0.07 per share, indicating a commitment to returning value to shareholders despite facing headwinds.
With a current P/E ratio of approximately 15, RVTY is positioned moderately compared to its industry peers, which average around 18.
The company’s earnings per share (EPS) is projected to decline by double digits in the upcoming quarter, reflecting difficulties particularly in its Diagnostic segment due to market pressures in China.
However, the Life Sciences segment is expected to show resilience, driven by rising demand.
Revenue forecasts suggest a potential rebound as the company expands its T1D diagnostics offerings in partnership with Sanofi, which could enhance long-term growth prospects.
Year-to-date, RVTY shares have underperformed with an 18% decline, contrasting sharply with a positive sector performance, where healthcare stocks have generally trended upwards.
Looking ahead, Revvity is set to release its Q3 earnings on October 27, 2025, and analysts are bracing for a significant drop in earnings, which may further impact investor sentiment.
Historical performance has shown volatility, and the consensus among analysts indicates caution, with many expecting challenges in meeting earnings estimates.
The upcoming earnings call will provide critical insights into the company’s operational adjustments and strategic initiatives, particularly in light of the recent expansion of its diagnostics capabilities.
The market will be keenly observing whether these efforts can translate into improved financial metrics and a more favorable outlook for RVTY.
Overall, the healthcare sector, to which Revvity belongs, has shown resilience, with many companies reporting growth despite economic uncertainties.
The broader market context suggests that while RVTY faces specific challenges, the sector's general upward trend may provide a supportive backdrop for potential recovery in the company's stock performance.
- Funds were net buyers of
$RVTY during the previous reporting quarter.
- Funds with large holdings in
$RVTY include:
- Rgm Capital LLC, MV:
$155MM. Fund Rank: 83%
www.rgmcapital.com
- Primecap Management, MV:
$132MM. Fund Rank: 63%
- King Luther Cap, MV:
$18MM. Fund Rank: 72%
- Parkman Healthcare Partners LLC, MV:
$15MM. Fund Rank: 59%
www.parkmanhp.com
- Sivik Global Healthcare LLC
, MV:
$4MM. New position. Fund Rank: 79%
www.sivik.com
- Last 10 days performance: 9%
- Last 30 days performance: 17%
- Last 90 days performance: -5%
Some of the latest news articles:
- Title: Revvity Board Declares Quarterly Dividend
Publication Date: 10/23/2025 8:05:00 PM, Source: yahoo
URL: https://finance.yahoo.com/news/revvity-board-declares-quarterly-dividend-200500793.html?.tsrc=rss
- Title: Will RVTY Q3 Earnings Reflect Segmental Strength Amid Rising Demand?
Publication Date: 10/23/2025 11:53:00 AM, Source: yahoo
URL: https://finance.yahoo.com/news/rvty-q3-earnings-reflect-segmental-115300204.html?.tsrc=rss
- Title: Revvity (RVTY) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
Publication Date: 10/22/2025 1:15:02 PM, Source: yahoo
URL: https://finance.yahoo.com/news/revvity-rvty-q3-earnings-preview-131502065.html?.tsrc=rss
- Title: Labcorp Holdings (LH) Reports Next Week: Wall Street Expects Earnings Growth
Publication Date: 10/21/2025 2:00:09 PM, Source: yahoo
URL: https://finance.yahoo.com/news/labcorp-holdings-lh-reports-next-140009467.html?.tsrc=rss
Follow us on stocktwits.com for more earnings alerts. Not a financial advice. Not a trading signal."
